This study used target trial emulation in a Korean national health insurance database to evaluate whether ICS escalation (vs. continuing LAMA/LABA) after a single moderate COPD exacerbation differs in benefit based on exacerbation treatment phenotype—antibiotic-treated vs. systemic corticosteroid-treated—in ICS-naïve patients.
ICS escalation after a steroid-treated moderate exacerbation reduced subsequent exacerbation risk (LAMA/LABA continuation HR 1.18, 95% CI 1.12–1.23 vs. ICS escalation). ICS escalation after an antibiotic-treated exacerbation showed no significant benefit over LAMA/LABA continuation.
Observational design with propensity score matching cannot fully exclude residual confounding. Exacerbation phenotype was defined by treatment received (antibiotics vs. systemic corticosteroids), which may not perfectly reflect underlying biology. Findings are from a single Asian (Korean) healthcare system and may not generalize globally.
When a COPD patient on LAMA/LABA has a moderate exacerbation requiring systemic corticosteroids, escalating to an ICS-containing regimen appears warranted. For antibiotic-only exacerbations, ICS escalation may not add benefit—consider the phenotype before stepping up therapy.
Explore related topics
